These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21130132)

  • 1. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder.
    Mick E; McGough JJ; Middleton FA; Neale B; Faraone SV
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):466-72. PubMed ID: 21130132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder.
    Mick E; Neale B; Middleton FA; McGough JJ; Faraone SV
    Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1412-8. PubMed ID: 18821564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD.
    Lee SH; Kim SW; Lee MG; Yook KH; Greenhill LL; Fradin KN; Hong HJ
    Psychiatry Res; 2011 Apr; 186(2-3):338-44. PubMed ID: 20863575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.
    Pelham WE; Burrows-Maclean L; Gnagy EM; Fabiano GA; Coles EK; Tresco KE; Chacko A; Wymbs BT; Wienke AL; Walker KS; Hoffman MT
    Exp Clin Psychopharmacol; 2005 May; 13(2):111-26. PubMed ID: 15943544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
    Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
    Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder.
    Cheon KA; Cho DY; Koo MS; Song DH; Namkoong K
    Biol Psychiatry; 2009 Apr; 65(7):564-70. PubMed ID: 19150055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.
    Flapper BC; Schoemaker MM
    Dev Med Child Neurol; 2008 Apr; 50(4):294-9. PubMed ID: 18352997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment.
    Gürkan K; Bilgiç A; Türkoglu S; Kiliç BG; Aysev A; Uslu R
    J Psychopharmacol; 2010 Dec; 24(12):1810-8. PubMed ID: 19939861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-ranging study of a methylphenidate transdermal system in children with ADHD.
    Pelham WE; Manos MJ; Ezzell CE; Tresco KE; Gnagy EM; Hoffman MT; Onyango AN; Fabiano GA; Lopez-Williams A; Wymbs BT; Caserta D; Chronis AM; Burrows-Maclean L; Morse G
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):522-9. PubMed ID: 15908834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD.
    Faraone SV; Glatt SJ; Bukstein OG; Lopez FA; Arnold LE; Findling RL
    J Atten Disord; 2009 Jan; 12(4):308-15. PubMed ID: 18400982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.